Press Releases

 

Financial

  Date Title and Summary View
Nov 14, 2017
Recent Minimally Dilutive Financings Substantially Strengthen Balance Sheet and Provide Runway to Significant Clinical Milestones for ThermoDox® and GEN-1 Clinical Programs Company to Hold Conference Call on Tuesday, November 14, 2017 at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CL...
Nov 7, 2017
LAWRENCEVILLE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of...
Oct 27, 2017
LAWRENCEVILLE, N.J., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of an underwritten offering of 2,640,000 shares of its common stock and warrants to purchase up to 1,320,000 shares of common stock at an offering price of $2.50 per share and related warrants. Each share of common ...
Oct 4, 2017
Financing Accomplished with Minimal New Equity Issuance Operating Runway Extended through 2018     LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into Exercise Agreements with the holders of existing warrants previously issued. On July 6, 2017, th...
Aug 15, 2017
LAWRENCEVILLE, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter and six month period ended June 30, 2017 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of...
Aug 8, 2017
LAWRENCEVILLE, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
Aug 4, 2017
Limited TASE Trading Activity Does Not Warrant Listing  Shares to Continue Listing and Trading on the NASDAQ Capital Market LAWRENCEVILLE, N.J., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it is taking steps to voluntarily delist the Company's common shares...
Jul 6, 2017
LAWRENCEVILLE, N.J., July 06, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct ...
Jun 22, 2017
LAWRENCEVILLE, N.J., June 22, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has cancelled the registered direct offering of common stock announced Monday, June 19, 2017. The Company had entered into security purchase agreements with three institutional investors to purchase shares of common sto...
Jun 19, 2017
LAWRENCEVILLE, N.J., June 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5.4 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direc...
Page:
1
... NextLast
= add release to Briefcase
Share This